MUC1 is a potential target to overcome trastuzumab resistance in breast cancer therapy

Hosseinzadeh, Aysooda; Merikhian, Parnaz; Naseri, Nazanin; Eisavand, Mohammad Reza; Farahmand, Leila

doi:10.1186/s12935-022-02523-z

Cited by 19 publications

(10 citation statements)

References 159 publications

(255 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, the overexpression of this membrane-bound glycoprotein limits the effectiveness of 5-fluorouracil treatment in patients with pancreatic cancer ( Kalra and Campbell 2009 ), and decreases sensitivity of cisplatin in SCC ( Zhao et al, 2021 ). Mucin 1 plays a key role in trastuzumab resistance in breast cancer ( Hosseinzadeh et al, 2022 ). The high-expression of MUC1 is associated with a poor prognosis for esophageal cancer patients ( Song et al, 2003 ), contributes to SCC metastasis ( Ye et al, 2011 ), and plays a pivotal role in the progression to AC ( Adil Butt et al, 2017 ).…”

Section: Discussionmentioning

confidence: 99%

Identification of Candidate Therapeutic Genes for More Precise Treatment of Esophageal Squamous Cell Carcinoma and Adenocarcinoma

Polewko-Klim

Zhu

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

The standard therapy administered to patients with advanced esophageal cancer remains uniform, despite its two main histological subtypes, namely esophageal squamous cell carcinoma (SCC) and esophageal adenocarcinoma (AC), are being increasingly considered to be different. The identification of potential drug target genes between SCC and AC is crucial for more effective treatment of these diseases, given the high toxicity of chemotherapy and resistance to administered medications. Herein we attempted to identify and rank differentially expressed genes (DEGs) in SCC vs. AC using ensemble feature selection methods. RNA-seq data from The Cancer Genome Atlas and the Fudan-Taizhou Institute of Health Sciences (China). Six feature filters algorithms were used to identify DEGs. We built robust predictive models for histological subtypes with the random forest (RF) classification algorithm. Pathway analysis also be performed to investigate the functional role of genes. 294 informative DEGs (87 of them are newly discovered) have been identified. The areas under receiver operator curve (AUC) were higher than 99.5% for all feature selection (FS) methods. Nine genes (i.e., ERBB3, ATP7B, ABCC3, GALNT14, CLDN18, GUCY2C, FGFR4, KCNQ5, and CACNA1B) may play a key role in the development of more directed anticancer therapy for SCC and AC patients. The first four of them are drug targets for chemotherapy and immunotherapy of esophageal cancer and involved in pharmacokinetics and pharmacodynamics pathways. Research identified novel DEGs in SCC and AC, and detected four potential drug targeted genes (ERBB3, ATP7B, ABCC3, and GALNT14) and five drug-related genes.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of Candidate Therapeutic Genes for More Precise Treatment of Esophageal Squamous Cell Carcinoma and Adenocarcinoma

Polewko-Klim

Zhu

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

show abstract

“…Resveratrol triggers a stepwise inhibition cascade involving Src tyrosine kinase and STAT3 proteins. In order to circumvent the problem of trastuzumab resistance in Her2+ patients, scientists have targeted the proto‐oncogene MUC1 , which is a downstream target of STAT3 [98]. 6Br‐6a is a STAT3 inhibitor that decreased cell proliferation, increased apoptosis and reduced plasticity making it a promising target in breast cancer [99].…”

Section: Potential Treatments Targeting Cell‐intrinsic Pathways Media...mentioning

confidence: 99%

Unraveling the dangerous duet between cancer cell plasticity and drug resistance

Chatterjee,

Pulipaka,

Subbalakshmi

et al. 2023

Comp Sys Onco

View full text Add to dashboard Cite

Cancer cell plasticity is the ability of tumor cells to switch phenotypes and is one of the predominant requisites of cancer cells capable of undergoing metastasis. Cancer cell plasticity is also recognized as one of the major contributors to intratumoral heterogeneity, a critical factor underlying the progression of malignant tumors, which is known to modify tumor response and induce resistance against various modes of therapy, thus posing a barrier to efficient cancer management. Cancer cell plasticity is acquired by the subversion of cell signaling pathways like mitogen‐activated protein kinase pathway, phosphoinositide‐3‐kinase, signal transducer and activator of transcription 3, Wnt, Hedgehog and Notch as well as cellular programs such as epithelial to mesenchymal transition and phenotypic plasticity. This complex phenomenon has been studied in many cancer types like pancreatic cancer, colon cancer and breast cancer. This review will explore the current understanding we have in breast cancer on the intrinsic molecular mechanisms of cancer cell plasticity and the resistance to various types of cancer therapy that arise as a result of plasticity. We conclude by exploring the potential novel therapies that specifically target the pathways leading to plasticity and can be leveraged to treat patients living with the disease.

show abstract

“…It has been shown that MUC1 promotes cell growth and the proliferation of cancer by regulating PI3K/AKT, MEK/ERK, p53, nuclear factor-κB, epidermal growth factor receptor, WNT/β-catenin and JNK/TGF-β ( 3 , 11 , 12 ). MUC1 also regulates tumour cell invasion and metastasis by interacting with E-calmodulin and intercellular adhesion molecules ( 13 , 14 ). In addition, MUC1 promotes tumour angiogenesis and accelerates the invasion and metastasis of tumours by stimulating the expression of proangiogenic factors, such as vascular endothelial growth factor ( 4 , 15 ).…”

Section: Distribution Structure and Biological Characteristics Of Muc1mentioning

confidence: 99%

Expression of MUC1 in different tumours and its clinical significance (Review)

Lan

Tai

2022

Mol Clin Oncol

View full text Add to dashboard Cite

Mucin 1 (MUC1) was the first discovered transmembrane protein of the mucin family; it normally covers epithelial cells of the mucous membrane, providing lubrication and protection. However, aberrant expression of MUC1 is involved in cancer development, invasion and metastasis. It has been reported that MUC1 upregulation is highly associated with the progression of different epithelial cancer types, such as lung, liver, pancreatic and breast cancer. Therefore, MUC1 can be used as a specific marker and a target for immunotherapy in clinical applications, and the detection of MUC1 expression levels can be used to diagnose the occurrence, metastasis, prognosis and recurrence of cancer. The present review summarizes the abnormal expression of MUC1 in different tumours and discusses its clinical significance, thereby highlighting the potential diagnostic and therapeutic significance of MUC1 in cancer.

show abstract

MUC1 is a potential target to overcome trastuzumab resistance in breast cancer therapy

Cited by 19 publications

References 159 publications

Identification of Candidate Therapeutic Genes for More Precise Treatment of Esophageal Squamous Cell Carcinoma and Adenocarcinoma

Identification of Candidate Therapeutic Genes for More Precise Treatment of Esophageal Squamous Cell Carcinoma and Adenocarcinoma

Unraveling the dangerous duet between cancer cell plasticity and drug resistance

Expression of MUC1 in different tumours and its clinical significance (Review)

Contact Info

Product

Resources

About